1. Home
  2. CCCC

as 09-29-2025 3:31pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.

Founded: 2015 Country:
United States
United States
Employees: N/A City: WATERTOWN
Market Cap: 175.1M IPO Year: 2020
Target Price: $8.50 AVG Volume (30 days): 1.8M
Analyst Decision: Strong Buy Number of Analysts: 4
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -1.58 EPS Growth: N/A
52 Week Low/High: $1.08 - $7.14 Next Earning Date: 10-30-2025
Revenue: $34,240,000 Revenue Growth: 16.55%
Revenue Growth (this year): -26.97% Revenue Growth (next year): -20.38%

CCCC Daily Stock ML Predictions

Share on Social Networks: